Amsterdam, 3 - 4 March 2026
Schedule
Create your personal agenda –check the favourite icon
Mar 38:00
Conference pass
Registration & Networking Meetings
Keynotes
Registration & Networking Meetings in the exhibition hall.
Mar 38:55
Conference pass
Chair's Remarks
Keynotes
Annette Powers, Senior Vice President, Global Access & Value and Public Policy (GAVP), Astellas
Mar 39:00
Conference pass
Session Reserved for Johnson & Johnson Innovative Medicine
Keynotes
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine
Mar 39:20
Conference pass
Session Reserved for ZS
Keynotes
Session Reserved for ZS
Mar 39:40
Conference pass
Session Reserved for Roche
Keynotes
Keynote presentation
Mar 310:00
Conference pass
Session Reserved for Parexel
Keynotes
Session Reserved for Parexel
Mar 310:20
Conference pass
Session Reserved for UCB
Keynotes
Keynote presentation
Sophie Janssens, Sr VP, Global Head of Patient Impact Maximization, UCB
Mar 310:40
Conference pass
Session reserved for Valid Insight
Keynotes
Session reserved for Valid Insight
Mar 311:55
Conference pass
Chair's Remarks
Real World Evidence & Data
Rhys Williams, Vice President, Evidence Generation Strategy and Health Economics, Global Medical Affairs (ex-China), BeOne Medicines
Mar 311:55
Conference pass
Chair's Remarks
Market Access
Riad Dirani, Vice President, Global Health Economics, Value and Outcomes, Teva Pharmaceuticals
Mar 311:55
Conference pass
Chair's Remarks
Pricing
Jiri Smejkal, Global Head of Pricing and Tender Excellence for PDT, Takeda
Mar 311:55
Conference pass
Chair's Remarks
HTA
Steen Werner Hansen, Former Chair Danish Medicines Council, Danish Medicines Council
Mar 311:55
Conference pass
Chair's Remarks
Pre-Launch Success
Mar 311:55
Conference pass
Chair's Remarks
Reimbursement
Lisette Kaskens, Director Value and Access, Ferring Pharmaceuticals
Mar 311:55
Conference pass
Chair's Remarks
Rare Diseases
Marcus Droege, Chief Commercial Officer, MUVON Therapeutics
Mar 311:55
Conference pass
Chair's Remarks
AI & Digital Transformation
Jean-Christophe Zeeh-Petite, Global Value & Access Director, Business Development and New Products Planning, Ipsen
Mar 311:55
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Sandeep Kiri, Global Head, Health Economic Evidence, UCB
Mar 311:55
Conference pass
Mar 312:00
Conference pass
AI’s impact on the patient doctor relationship
AI & Digital Transformation
Reserved for the Council of Europe.
Mar 312:00
Conference pass
Commercializing in-licensed assets and setting them up for global success
Pre-Launch Success
Anupama Rao Singh, Vice President, LATAM/Head Oncology COE, Dr. Reddy's Laboratories Ltd.
Mar 312:00
Conference pass
Equity of access in Portugal: minimising access challenges
Sustainable Access & Policy
Mar 312:00
Conference pass
Implementation of real-world data to move the needle on access policy
Real World Evidence & Data
Vanessa Mirsky, Vice President, Life Sciences Data Strategy, RWE/RWD, OneOncology
Mar 312:00
Conference pass
Improved health outcomes of therapeutic adherence for positive economic impact
Health Economics & Outcomes Research
Gianfranco Parlato, Global Head of Value Access & Pricing CVMD (CardioMetabolism & Venous Disease), Servier Monde
Mar 312:00
Conference pass
Innovative treatments for neurological diseases: challenges in access and policy
Rare Diseases
Mohit Jain, Vice President, Market Access, International Operations, IntraBio
Mar 312:00
Conference pass
Latest trends in US market access
Market Access
Reg Waldeck, Vice President, Head Global Market Access, Bayer
Mar 312:00
Conference pass
Optimal reimbursement decision making processes in healthcare
Reimbursement
Mar 312:00
Conference pass
Realities and trends for international reference pricing
Pricing
Walmon Leal, Vice President, Head of Global Pricing, Tenders & Contracts, Viatris
Mar 312:00
Conference pass
Speaker presentation
HTA
Speaker presentation
Mar 312:20
Conference pass
Session Reserved for Access Infinity
Market Access
Session Reserved for Access Infinity
Mar 312:20
Conference pass
Session Reserved for Cellbyte
AI & Digital Transformation
Session Reserved for Cellbyte
Mar 312:20
Conference pass
Session Reserved for Initiate
Health Economics & Outcomes Research
Session Reserved for Initiate
Mar 312:20
Conference pass
Session Reserved for Remap
HTA
Session Reserved for Remap
Mar 312:20
Conference pass
Session Reserved for Stratence Partners
Pricing
Session Reserved for Stratence Partners
Mar 312:20
Conference pass
Sponsor presentation
Real World Evidence & Data
Sponsor presentation
Mar 312:20
Conference pass
Sponsor presentation
Pre-Launch Success
Sponsor presentation
Mar 312:20
Conference pass
Sponsor presentation
Reimbursement
Sponsor presentation
Mar 312:20
Conference pass
Sponsor presentation
Rare Diseases
Sponsor presentation
Mar 312:20
Conference pass
Sponsor presentation
Sustainable Access & Policy
Sponsor presentation
Mar 312:40
Conference pass
Adopting a societal perspective for the full value of pharmaceutical innovation
Sustainable Access & Policy
Jose Diaz, Global Health Systems Economics & Value of Innovation, BMS
Mar 312:40
Conference pass
Capabilities and innovations for the future of access
Market Access
Iroda Jurabekova, Global Director, Oncology Pricing and Market Access, Boehringer Ingelheim
Mar 312:40
Conference pass
Challenges for combination pricing
Pricing
Sandra Margunato Debay, Senior Director, Global Market Access and Pricing, Genmab
Mar 312:40
Conference pass
From academic development to the market: data challenges for rare disease access
Rare Diseases
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Mar 312:40
Conference pass
Practical use cases of GenAI for HTA
AI & Digital Transformation
Sven Klijn, Director, HEOR Economic & Predictive Modeling, Bristol Myers Squibb
Mar 312:40
Conference pass
Reimbursement models in Israel: comparisons with Europe
Reimbursement
Tomer Benzaken, Director, Head of Commercial Operations & Trade, Astellas
Mar 312:40
Conference pass
Risk awareness for HTA decision making across Europe
HTA
Hans Severens, Independent HTA Expert, Severens HTA consultancy
Mar 312:40
Conference pass
Successful launch for oncology rare diseases
Pre-Launch Success
Sandy Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore
Mar 312:40
Conference pass
The value of real world evidence and data in bringing products to market
Real World Evidence & Data
Cristina Valencia, Associate Director, Real World Evidence, Takeda
Mar 312:40
Conference pass
Title TBC
Health Economics & Outcomes Research
Silvy Mardiguian, Head of HEOR, Europe & New Markets, BeOne Medicines
Mar 313:00
Conference pass
Session Reserved for Asc Academics
Health Economics & Outcomes Research
Session Reserved for Asc Academics
Mar 313:00
Conference pass
Session Reserved for Blue Matter
Pre-Launch Success
Session Reserved for Blue Matter
Mar 313:00
Conference pass
Session Reserved for Decisive Consulting
Market Access
Session Reserved for Decisive Consulting
Mar 313:00
Conference pass
Session Reserved for Precision AQ
Pricing
Session Reserved for Precision AQ
Mar 313:00
Conference pass
Session Reserved for Stratence Partners
AI & Digital Transformation
Session Reserved for Stratence Partners
Mar 313:00
Conference pass
Sponsor presentation
Reimbursement
Sponsor presentation
Mar 313:00
Conference pass
Sponsor presentation
Rare Diseases
Sponsor presentation
Mar 313:00
Conference pass
Sponsor presentation
Sustainable Access & Policy
Sponsor presentation
Mar 313:00
Conference pass
Sponsor presentation
Real World Evidence & Data
Sponsor presentation
Mar 313:00
Conference pass
Sponsor presentation
HTA
Sponsor presentation
Mar 313:20
Conference pass
Lunch
Keynotes
Lunch options available for purchase in the exhibition hall.
Mar 314:45
Conference pass
01 Real World Evidence & Data Panel – Supporting economic evaluation in digital health: practical insights from CHEERS-DHI
Real World Evidence & Data
Moderator: Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Carl Asche, Executive Director, Pharmacotherapy Outcomes Research Center, University of Utah
Mar 314:45
Conference pass
02 Market Access Panel – Access Infinity
Market Access
Panel Discussion Reserved for Access Infinity
Mar 314:45
Conference pass
03 Pricing Panel – Inbeeo
Pricing
Panel Discussion Reserved for Inbeeo
Ulf Staginnus, Vice President, International Market Access & Pricing, Blueprint Medicines
Mar 314:45
Conference pass
04 HTA Panel – Redthread Market Access
HTA
Panel Discussion Reserved for Redthread Market Access
Mar 314:45
Conference pass
05 Pre-Launch Success Panel – Enabling successful product launches: from global to local, planning for success
Pre-Launch Success
Moderator: Kevyn Adler, Senior Director, Market Access Product & Pipeline Strategy, Regeneron
Fabian Schmidt, Global Head of Value, Access & Policy, Recordati Rare Diseases
Sabrina Aouabed, Head of Market Access France, GSK
Hedwig Silies, Senior Director, Pricing & Market Access, DACH & Nordic Countries Lead, Blueprint Medicines
Jolanda Koenders, Head of Launch Excellence & New Product Planning, Central South East Europe, Takeda
Mar 314:45
Conference pass
06 Reimbursement Panel - Access by design: reinventing how oncology innovation reaches patients
Reimbursement
Clifford Samuel, Former Senior Vice President, Gilead & Fellow, Harvard University
Aparna Parikh, Associate Professor of Medicine and Director, Cancer Center Global Cancer Care Program, Massachusetts General Hospital
Mar 314:45
Conference pass
07 Rare Diseases Panel – Leveraging JCA experiences for rare disease access
Rare Diseases
Moderator: Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Peter Pemberton-Ross, Head, HE & HTA Strategy, Biogen International GmbH
Lorenzo Capretto, Market Access Lead EU&EM, Global Rare Disease, Chiesi Farmaceutici SpA
Patrick Hopkinson, Independent HTA Expert, Independent HTA Expert
Lora Fleifel, Director, Market Access & Pricing, Europe, Oncology, Merck Pte. Ltd.
Mar 314:45
Conference pass
08 AI & Digital Transformation Panel – Where are we now for GenAI for HTA?
AI & Digital Transformation
Moderator: Bill Malcolm, Executive Director, Global HEOR Economic & Predictive Modelling, Bristol Myers Squibb
Katja Berg, Global Value and Access Strategy, BBU, AstraZeneca
Rosa Maria Vivanco Hidalgo, Head of Health Technology Assessment, AQuAS Gencat
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Mar 314:45
Conference pass
09 HTA Panel – The JCA as a pathway to EU joint procurement?
Health Economics & Outcomes Research
Valentina Strammiello, Director of Strategic Initiatives, European Patients' Forum
Elke Hunsche, CEO, Auristra Consult GmbH
Marlene Gyldmark, EU HTA lead, BeOne Medicines
Mar 314:45
Conference pass
10 Sustainable Access & Policy Panel – Industry and government collaborations for market access to lower and middle income countries
Sustainable Access & Policy
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
Carin Uyl-de Groot, Professor of HTA, Erasmus University Rotterdam
Mar 315:45
Conference pass
Chair's Remarks
Real World Evidence & Data
Chair Remark's
Maurice Driessen, Senior Director, Head of Inline Brands, GHEVO, Teva Pharmaceuticals
Mar 315:45
Conference pass
Chair's Remarks
Market Access
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Mar 315:45
Conference pass
Chair's Remarks
Pricing
Eric Noehrenberg, Founder, NIPC
Mar 315:45
Conference pass
Chair's Remarks
HTA
Filippo Drago, Full Professor of Clinical Pharmacology, University of Catania
Mar 315:45
Conference pass
Chair's Remarks
Pre-Launch Success
Gorana Capkun, Vice President, Global Head of Patient Focused Real World Evidence, Merck Group
Mar 315:45
Conference pass
Chair's Remarks
Reimbursement
Chair's Remarks
Mar 315:45
Conference pass
Chair's Remarks
Rare Diseases
Stefaan Fiers, Chapter Head, External Affairs, Roche
Mar 315:45
Conference pass
Chair's Remarks
AI & Digital Transformation
Peter Takacs, Head of Global Market Access, Miltenyi Biomedicine
Mar 315:45
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Montserrat Vera-Llonch, Executive Director, Global HEOR, Ionis Pharmaceuticals
Mar 315:45
Conference pass
Chair's Remarks
Sustainable Access & Policy
Mar 315:50
Conference pass
Accessibility and time to reimbursement of treatments with substantial benefit: A comparative analysis focused on inequalities between different European countries and different tumor types
Market Access
Mar 315:50
Conference pass
Advancing the patient voice in rare disease access
Rare Diseases
Antonella Cardone, CEO, Cancer Patients Europe
Mar 315:50
Conference pass
Challenges in building HEOR frameworks
Health Economics & Outcomes Research
Kun Shi-van Wielink, Director, HEOR/RWE, Market Access, EMEA, Santen
Mar 315:50
Conference pass
Current use cases and prospects for GenAI in market access
AI & Digital Transformation
Jag Chhatwal, Director, Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School
Mar 315:50
Conference pass
Reimbursement models and HTA for digital health technologies: updates from the EDiHTA project
Reimbursement
Emmanouil Tsiasiotis, Research Project Manager and Coordinator, EDiHTA
Mar 315:50
Conference pass
The strategic value of integrated evidence activities for launch success
Pre-Launch Success
Melvin Skip Olson, Founder, Olson Strategies GmbH
Mar 315:50
Conference pass
Using a tiered pricing strategy vs a single GFP: pros and cons
Pricing
Loic Gauthier, Global Pricing Director, CSL Behring
Mar 315:50
Conference pass
Utilizing tokenization tools to enable patient incentives for real world evidence generation
Real World Evidence & Data
Vidya Breeveld, CEO, Transmineo
Mar 315:50
Conference pass
What has SUSTAIN-HTA brought to HTA in Europe in the last year?
HTA
Wim Goettsch, Special Advisor HTA & Professor for HTA of Pharmaceuticals, Zorginstituut & Utrecht University
Mar 316:10
Conference pass
Session Reserved for Lifescience Dynamics
Pre-Launch Success
Session Reserved for Lifescience Dynamics
Mar 316:10
Conference pass
Session Reserved for PharmacoEvidence
AI & Digital Transformation
Session Reserved for PharmacoEvidence
Mar 316:10
Conference pass
Sponsor presentation
Rare Diseases
Sponsor presentation
Mar 316:10
Conference pass
Sponsor presentation
Real World Evidence & Data
Sponsor presentation
Mar 316:10
Conference pass
Sponsor presentation
Reimbursement
Sponsor presentation
Mar 316:10
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Sponsor presentation
Mar 316:10
Conference pass
Sponsor presentation
Sustainable Access & Policy
Sponsor presentation
Mar 316:10
Conference pass
Sponsor presentation
Market Access
Sponsor presentation
Mar 316:10
Conference pass
Sponsor presentation
Pricing
Sponsor presentation
Mar 316:10
Conference pass
Sponsor presentation
HTA
Sponsor presentation
Mar 316:30
Conference pass
Barriers and solutions for the uptake of novel medicines in the UK
HTA
Phil Jennings, Vice Chair, NHS Health Innovation Network
Mar 316:30
Conference pass
Creating a roadmap for market access: how to advocate for access internally
Market Access
Ana Filipa Alexandre, Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals
Mar 316:30
Conference pass
Enabling access through the use of AI
AI & Digital Transformation
James Rose, Director of Industry Partnerships, Health Innovation Oxford
Mar 316:30
Conference pass
Impacts of environmental sustainability factors on European market access
Sustainable Access & Policy
Silvia de Diego Blanco, Director, Global Market Access, Astellas
Mar 316:30
Conference pass
Influencing without authority: communicating effectively across functions and stakeholders
Health Economics & Outcomes Research
Natalia Scherff, Leadership Coach, ICF PCC, Coach Scherff
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine
Mar 316:30
Conference pass
Mobilising integrated evidence plans for launch success
Real World Evidence & Data
Mar 316:30
Conference pass
Reasons for alternative contracting: when does it make sense?
Pricing
Sara Engstrand, Senior Market Access Manager, Pfizer
Mar 316:30
Conference pass
The bumpy and uncertain road to access in the NLs
Reimbursement
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Mar 316:30
Conference pass
The longevity imperative, a changing innovation ecosystem and early market access strategy
Pre-Launch Success
Elena Tricca, Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca
Mar 316:30
Conference pass
Understanding definitions of unmet medical needs in the context of rare diseases
Rare Diseases
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA & APAC, PTC Therapeutics
Mar 316:50
Conference pass
Networking Break
Keynotes
Networking Break
Mar 317:20
Conference pass
Chair's Remarks
Real World Evidence & Data
Chair's Remarks
Mar 317:20
Conference pass
Chair's Remarks
Market Access
Chair's Remarks
Mar 317:20
Conference pass
Chair's Remarks
Pricing
Chair's Remarks
Adam Kundzewicz, Head of Market Access and Healthcare Affairs, HP MIDI
Mar 317:20
Conference pass
Chair's Remarks
HTA
Chair's Remarks
Mar 317:20
Conference pass
Chair's Remarks
Pre-Launch Success
Chair's Remarks
Mar 317:20
Conference pass
Chair's Remarks
Sustainable Access & Policy
Chair's Remarks
Mar 317:20
Conference pass
Chair's Remarks
Rare Diseases
Chair's Remarks
Jan Swiderski, Head of Government Affairs & Policy, Kyowa Kirin International
Mar 317:20
Conference pass
Chair's Remarks
AI & Digital Transformation
Chair's Remarks
Mar 317:20
Conference pass
Chair's Remarks
Reimbursement
Chair's Remarks
Mar 317:20
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Chair's Remarks
Mar 317:25
Conference pass
Sponsor presentation
Real World Evidence & Data
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
Market Access
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
Sustainable Access & Policy
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
Reimbursement
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
Pricing
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
HTA
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
Pre-Launch Success
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
Rare Diseases
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
AI & Digital Transformation
Sponsor presentation
Mar 317:25
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Sponsor presentation
Mar 317:45
Conference pass
Access policy and changes to the funding landscape
Sustainable Access & Policy
Speaker presentation
Billy West, Equitable Access Lead, Wellcome Trust
Mar 317:45
Conference pass
Advancing GenAI for orphan disease access
AI & Digital Transformation
Ning Lu, Director, International Market Access and Pricing, Blueprint Medicines
Mar 317:45
Conference pass
How to navigate and facilitate access for precision medicines and companion diagnostics
Market Access
Natasa Zibelnik, Global Head of Market Access and Reimbursement, Oncology, Menarini Stemline
Mar 317:45
Conference pass
Multi-stakeholder engagement to advance access and reimbursement in pediatric indications
Reimbursement
Fabian Haacke, Director, Access Evidence, Santen
Mar 317:45
Conference pass
Patient registries as an evidence backbone for rare conditions
Rare Diseases
Lotta Parviainen, Global Market Access Director, Zambon France
Mar 317:45
Conference pass
Pre-launch and market access strategies for start ups
Pre-Launch Success
Stephanie Juniat, Director, Alethira
Mar 317:45
Conference pass
Rebalancing pharmaceutical expenditure: what is the optimal level of spending on pharmaceuticals and healthcare? (The Reframe Project)
Pricing
Speaker presentation
Adam PARNABY, Lead, Global Policy & Access, Bristol Myers Squibb
Mar 317:45
Conference pass
Risk aversion and health insurance: long terms perspectives on thresholds for real world evidence
Real World Evidence & Data
Jörg Mahlich, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Mar 317:45
Conference pass
Speaker presentation
Health Economics & Outcomes Research
Speaker presentation
Mar 317:45
Conference pass
Why do we have different reimbursement decisions based on similar evidence?
HTA
Goedele van Haasteren, Deputy Chief of the HTA Unit, Federal Office of Public Health, Switzerland
Mar 318:05
Conference pass
Close of conference and drinks reception
Keynotes
Close of conference and drinks reception in the main exhibition hall.
Create your personal agenda –check the favourite icon
Mar 48:55
Conference pass
Chair's Remarks
Keynotes
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Mar 49:00
Conference pass
AI, are we ready? Or is it a hype?
Keynotes
Arup Pramanik, Corporate Vice President, Global Market Access, Boehringer Ingelheim
Mar 49:20
Conference pass
Session Reserved for Lifescience Dynamics
Keynotes
Session Reserved for Lifescience Dynamics
Mar 49:40
Conference pass
Keynote presentation
Keynotes
Vivian Mendonca, Senior Vice President, Global Head - Value Evidence and External Affairs (G-VEEA), Menarini Group
Mar 410:00
Conference pass
Diamond sponsor
Keynotes
Diamond sponsor
Mar 410:20
Conference pass
Keynote Panel Discussion - How to succeed in market access? Navigating collaboration to deliver market access excellence
Keynotes
Moderator: Chris Mancill, Senior Vice President, Head, US Market Access, AstraZeneca
Annette Powers, Senior Vice President, Global Access & Value and Public Policy (GAVP), Astellas
Vivian Mendonca, Senior Vice President, Global Head - Value Evidence and External Affairs (G-VEEA), Menarini Group
Charles Makin, Head of US Real World Evidence & Epidemiology, Boehringer Ingelheim
Mar 411:00
Conference pass
Morning Break & Poster Sessions
Keynotes
Poster Sessions in the main exhibition hall.
Mar 411:55
Conference pass
Chair's Remarks
Real World Evidence & Data
Elena Panitti, Global Director, Evidence Valuation and Enablement, Novartis
Mar 411:55
Conference pass
Chair's Remarks
Market Access
Igor Solev, Global Head, Market Access, Policy & External Payer Affairs, Abbott Laboratories
Mar 411:55
Conference pass
Chair's Remarks
Pricing
Chair's Remarks
Stephen Connell, Executive Director, Global Market Access & Pricing, BioCryst Pharmaceuticals
Mar 411:55
Conference pass
Chair's Remarks
HTA
Chair's Remarks
Mar 411:55
Conference pass
Chair's Remarks
Pre-Launch Success
Chair's Remarks
Mar 411:55
Conference pass
Chair's Remarks
Reimbursement
Floortje van Nooten, Head of Market Access EU, Shionogi BV
Mar 411:55
Conference pass
Mar 411:55
Conference pass
Chair's Remarks
AI & Digital Transformation
Nadia Benhadi, Eu Market Access And Pricing Director, GlaxoSmithKline
Mar 411:55
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Chair's Remarks
Mar 411:55
Conference pass
Chair's Remarks
Sustainable Access & Policy
Krijn Schiffers, Operations Lead, Europe, Merck KGaA
Mar 412:00
Conference pass
A not-for-profit approach to pricing and access to an ex-vivo gene therapy for an ultra-rare disease
Rare Diseases
Reserved for Fondazione Telethon
Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon
Mar 412:00
Conference pass
Contract locally, think globally: The new rules of drug pricing
Pricing
Sandro Cesaro, Head of Europe Market Access & Pricing, AstraZeneca
Mar 412:00
Conference pass
Coordinating strategies for successful launches of multi-indication products
Pre-Launch Success
Tina Fischer, Head of Health Technology Assessments, Oncology, Daiichi-sankyo
Mar 412:00
Conference pass
Cross-functional integrated evidence planning: supporting the drug development lifecycle
Real World Evidence & Data
Tasi Lampropoulou, Director, Global Integrated Evidence Planning, Novartis
Mar 412:00
Conference pass
Embedding value at the heart of Merck
Market Access
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Mar 412:00
Conference pass
Integrating AI ways of working into an evolving structure
AI & Digital Transformation
Aodan Tynan, Head of Access Implementation, Pricing & Value Demonstration, Astellas
Mar 412:00
Conference pass
Patient relevant outcomes: Germany’s example in strengthening patient voices
Sustainable Access & Policy
Eva Susanne Dietrich, Professor, Departments for Clinical Pharmacy and Regulatory Affairs, University of Bonn
Mar 412:00
Conference pass
Rigorous execution of AI in HTA submissions
HTA
Mar 412:00
Conference pass
The gaps between reimbursement policies for AMR
Reimbursement
Durgesh Kahol, Global Pricing and Market Access Director, GSK
Mar 412:00
Conference pass
Why do so many rare disease treatments fail to reach patients outside the U.S., and how might emerging policies further exacerbate this access gap?
Health Economics & Outcomes Research
Joel Iff, Executive Director, Global Access, Value & Evidence, Sarepta Therapeutics
Mar 412:20
Conference pass
Session Reserved for Kintiga
Market Access
Session Reserved for Kintiga
Mar 412:20
Conference pass
Session Reserved for PharmacoEvidence
Health Economics & Outcomes Research
Sponsor presentation
Mar 412:20
Conference pass
Sponsor presentation
Real World Evidence & Data
Sponsor presentation
Mar 412:20
Conference pass
Sponsor presentation
Pricing
Sponsor presentation
Mar 412:20
Conference pass
Sponsor presentation
HTA
Sponsor presentation
Mar 412:20
Conference pass
Sponsor presentation
Pre-Launch Success
Sponsor presentation
Mar 412:20
Conference pass
Sponsor presentation
Reimbursement
Sponsor presentation
Mar 412:20
Conference pass
Sponsor presentation
Rare Diseases
Sponsor presentation
Mar 412:20
Conference pass
Sponsor presentation
AI & Digital Transformation
Sponsor presentation
Mar 412:20
Conference pass
Sponsor presentation
Sustainable Access & Policy
Sponsor presentation
Mar 412:40
Conference pass
Are rebate contracts always better for sick funds in Germany?
Pricing
Joshua Smeltzer, Global Pricing Director, Ipsen Pharma GmbH
Mar 412:40
Conference pass
Ensuring launch success in volatile access environments
Pre-Launch Success
Nidhi Dani, Global Pricing and Market Access Director, GSK
Mar 412:40
Conference pass
Fundamentals of market access for rare disease treatments in China
Rare Diseases
Speaker presentation
Mar 412:40
Conference pass
Implications of geopolitics on access and policy
Market Access
Neil Grubert, Global Market Access Expert, Independent
Mar 412:40
Conference pass
Maximising the use of the One London Data Programme for evidence and market access
Real World Evidence & Data
Mark Kewley, Director, London Secure Data Environment
Mar 412:40
Conference pass
Mind the gap: evidence requirements for regulatory, evaluation and adoption
HTA
Brad Groves, Director, NICE Advice, The National Institute for Health and Care Excellence (NICE)
Mar 412:40
Conference pass
New trends for reimbursement in Spain
Reimbursement
José Luis Sánchez Chorro, Market Access Director, Former Regional Pharmacy Director
Mar 412:40
Conference pass
The future of AI in market access
AI & Digital Transformation
Speaker presentation
Marco Rauland, Vice President, Market Access, Strategy, Pricing and Analytics, Merck KGaA
Mar 412:40
Conference pass
The untapped potential of comprehensive genomic profiling
Health Economics & Outcomes Research
Speaker presentation
Moderator: Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 412:40
Conference pass
Value added medicines: assessment frameworks and pathways to reimbursement
Sustainable Access & Policy
Marta Andreykiv, Head of Market Access Europe, Viatris
Mar 413:00
Conference pass
Session Reserved for TWS Partners
Market Access
Session Reserved for TWS Partners
Mar 413:00
Conference pass
Sponsor presentation
Pricing
Sponsor presentation
Mar 413:00
Conference pass
Sponsor presentation
Pre-Launch Success
Sponsor presentation
Mar 413:00
Conference pass
Sponsor presentation
Reimbursement
Sponsor presentation
Mar 413:00
Conference pass
Sponsor presentation
Rare Diseases
Sponsor presentation
Mar 413:00
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Sponsor presentation
Mar 413:00
Conference pass
Sponsor presentation
AI & Digital Transformation
Sponsor presentation
Mar 413:00
Conference pass
Sponsor presentation
Sustainable Access & Policy
Sponsor presentation
Mar 413:00
Conference pass
Sponsor presentation
Real World Evidence & Data
Sponsor presentation
Mar 413:00
Conference pass
The state of play for the HTA regulation: one year on
HTA
Erik Sagdahl, Policy Officer, DG Santé, European Commission
Mar 413:20
Conference pass
Lunch
Keynotes
Lunch options available in the exhibition hall.
Mar 414:45
Conference pass
01 Real World Evidence & Data Panel – Generating evidence to prepare for product launches
Real World Evidence & Data
Moderator: Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Johnson & Johnson Innovation
Patricia Dorling, Senior Director, Value & Implementation Outcomes Research, Oncology, Merck
Madhu Kabra, Global Director, HEOR, MKGlobal
Mar 414:45
Conference pass
02 Market Access Panel – Success stories for access to cell and gene therapies in Europe
Market Access
Moderator: Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Dilip Patel, SVP, Access & Market Development, Autolus
Petter Foss, Executive Director Value and Access Region Europe, Novartis
Andrew Olaye, Executive Director, Head of Market Access EMEA, Orchard Therapeutics Ltd
Mar 414:45
Conference pass
03 Pricing Panel – Most favored nation policy implications for global pricing strategies
Pricing
Moderator: Catarina Costa-Pinheiro, Head of Global Pricing, Ferrer Internacional
Elizabeth Kinter, Vice President, Head of Global Market Access, Avidity Biosciences
Luca Luigi Polastri, Global Value and Access Head, Nephrology Franchise, Kyowa Kirin
Giovanni Tafuri, Senior Director, International Market Access and Pricing, Madrigal Pharmaceuticals
Seema Sondhi, Independent Market Access Expert, Independent Market Access Expert
Ulrik Haagen Panton, Vice President, Global Pricing, NOVO NORDISK A/S
Mar 414:45
Conference pass
04 HTA Panel – EU HTA one year later, where are we?
HTA
Moderator: Mondher Toumi, Professor of Public Health, Aix-Marseille University
Josep Maria Guiu Segura, Head of Pharmacy, Hospital de Santa Tecla i Sant Pau
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Mar 414:45
Conference pass
05 Pre-Launch Success Panel – Lifescience Dynamics
Pre-Launch Success
Panel discussion reserved for Lifescience Dynamics.
Mar 414:45
Conference pass
06 Reimbursement Panel - Wickenstones
Reimbursement
Panel discussion reserved for Wickenstones.
Mar 414:45
Conference pass
07 Rare Diseases Panel - How to balance the needs of patients, healthcare systems and industry when assessing medicines for rare diseases?
Rare Diseases
Moderator: Jonathan Randell, Head of Value and Access, UK & Ireland, Biogen
Thomas Grub, Director, Global Pricing and Market Access, medac GmbH
Josie Godfrey, Independent Market Access and Rare Disease Adviser, Independent Rare Disease Expert
Stefano Losi, Market Access Lead, Europe & International Markets, Chiesi Group
Rachel Daley, Stakeholder Engagement Coordinator, University of Liverpool (CELT)
Christian Griffiths, Principal Technical Adviser - Rare Diseases, The National Institute for Health and Care Excellence (NICE)
Mar 414:45
Conference pass
08 AI & Digital Transformation Panel – Leveraging the European Health Data Space to advance reimbursement for digital behavior change interventions
AI & Digital Transformation
Moderator: Katarzyna Kolasa, Director, Digital Health Center, Kozminski University
Line Linstad, Director, Norwegian Centre for E-health Research
Fleur Levrat-Guillen, Director, Global Health Economics & Outcomes Research, Abbott Laboratories
Mar 414:45
Conference pass
09 Real World Evidence & Data Panel – Sponsor Reserved
Health Economics & Outcomes Research
Session reserved
Mar 414:45
Conference pass
10 Sustainable Access & Policy Panel – The dynamics of drug shortages in Europe: sustainable pricing for post-LOE products
Sustainable Access & Policy
Moderator: Delphine Courmier, Executive Director, Global Head of Pricing, Biosimilar Market Access, Organon
Amanda Cole, Director, Office of Health Economics
Mar 415:45
Conference pass
Chair's Remarks
Real World Evidence & Data
Chair's Remarks
Mar 415:45
Conference pass
Chair's Remarks
Market Access
Chair's Remarks
Mar 415:45
Conference pass
Chair's Remarks
Pricing
Chair's Remarks
Mar 415:45
Conference pass
Chair's Remarks
HTA
Chair's Remarks
Mar 415:45
Conference pass
Chair's Remarks
Pre-Launch Success
Chair's Remarks
Mar 415:45
Conference pass
Chair's Remarks
Reimbursement
Chair's Remarks
Mar 415:45
Conference pass
Chair's Remarks
Rare Diseases
Chair's Remarks
Charlotte Litrowski, Head of Market Access & Pricing EMEA & RoW, SERB Pharmaceuticals
Mar 415:45
Conference pass
Chair's Remarks
AI & Digital Transformation
Chair's Remarks
Mar 415:45
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Chair's Remarks
Mar 415:45
Conference pass
Chair's Remarks
Sustainable Access & Policy
Chair's Remarks
Mar 415:50
Conference pass
Challenges and solutions for reimbursement in the Netherlands
Reimbursement
Speaker presentation
Thomas Broekhoff, Project Manager, hollandbio
Mar 415:50
Conference pass
Early evidence generation across product lifecycle in Europe
Real World Evidence & Data
Speaker presentation
Martine Lewi, Independent Real World Evidence & Data Expert, Independent Real World Evidence & Data Expert
Mar 415:50
Conference pass
Lessons learned from the launch of a Haemophilia B gene therapy: do's and don'ts from an access perspective
Rare Diseases
Speaker presentation
Lara Pippo, Head of Market Access & Government Affairs, Italy, CSL
Mar 415:50
Conference pass
Market access involvement in early product planning
Pre-Launch Success
Speaker presentation
Jean-Christophe Zeeh-Petite, Global Value & Access Director, Business Development and New Products Planning, Ipsen
Mar 415:50
Conference pass
Speaker presentation
Pricing
Speaker presentation
Mar 415:50
Conference pass
Speaker presentation
HTA
Speaker presentation
Mar 415:50
Conference pass
Speaker presentation
Health Economics & Outcomes Research
Speaker presentation
Mar 415:50
Conference pass
Speaker presentation
Sustainable Access & Policy
Speaker presentation
Mar 415:50
Conference pass
Success for HTA processes in single arm trials in Germany
Market Access
Mar 415:50
Conference pass
The AI advantage: Sanofi's market access transformation journey
AI & Digital Transformation
Speaker presentation
Mathieu Giraud, Global Head of Market Access Digital Transformation, Sanofi
Benoit Miry, Head of Market Access General Medicines, France, Sanofi
Mar 416:10
Conference pass
Sponsor presentation
Market Access
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
Pricing
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
HTA
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
Pre-Launch Success
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
Reimbursement
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
Rare Diseases
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
AI & Digital Transformation
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
Sustainable Access & Policy
Sponsor presentation
Mar 416:10
Conference pass
Sponsor presentation
Real World Evidence & Data
Sponsor presentation
Mar 416:30
Conference pass
Speaker presentation
Rare Diseases
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
Real World Evidence & Data
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
Market Access
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
Pricing
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
HTA
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
Pre-Launch Success
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
Reimbursement
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
AI & Digital Transformation
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
Health Economics & Outcomes Research
Speaker presentation
Mar 416:30
Conference pass
Speaker presentation
Sustainable Access & Policy
Speaker presentation
Mar 416:50
Conference pass
Close of conference
Keynotes
Close of conference
last published: 16/Dec/25 14:05 GMT
Get Involved
Sponsorship & Exhibition Sales
Oliver Hersey-Swan
oliver.hersey-swan@terrapinn.com
Conference Production
George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940
Marketing Opportunities
Hidy Lee
hidy.lee@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events